Sprott Inc’s Pfizer PFE Stock Holding History

Sprott Inc’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-524,470	Closed	-$16.9M	–	190
2016 Q3	$16.9M	Hold	524,470	–	–	0.6%	39
2016 Q2	$17.5M	Buy	+524,470	New	+$16.7M	0.9%	36

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Sprott Inc's PFE Position: Q1 2017 in Review

Sprott Inc sold out of Pfizer (PFE) in Q1 2017, closing a stake of 564,976 shares — an estimated $17.4M sold.

Sprott Inc first reported a position in PFE in Q4 2013 and held it in 13 quarters. The position peaked at $36.1M in Q2 2016. 2,074 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

Sprott Inc reported no remaining Pfizer position as of Q1 2017 after selling out during the quarter.
Sprott Inc sold 564,976 Pfizer shares in Q1 2017, an estimated $17.4M.
Sprott Inc first reported a position in Pfizer in Q4 2013 and held it in 13 quarters.
Sprott Inc's Pfizer position peaked at $36.1M in Q2 2016.
2,074 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on Sprott Inc's 13F filing for Q1 2017, filed 8 May 2017.